Up after co resumes clinical studies halted for COVID-19
18/05/2020 16:12
** Drug developer's shares NCNA.O rise 2% to $5.64
** NuCana re-commences enrollment of new patients in
multiple clinical studies following a temporary pause due to the
coronavirus outbreak urn:newsml:reuters.com:*:nGNE8wjLZS
** Says early stage studies of its experimental cancer
treatments, NUC-3373 and NUC-7738, have reopened
** Company has reopened late-stage study of its experimental
treatment, Acelarin plus cisplatin, in patients with biliary
tract cancer on May 5
** NCNA has fallen ~7.5% YTD, as of Friday's close
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))